Literature DB >> 8916800

Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the Plasmodium falciparum circumsporozoite protein by sera from human donors.

J A Lopez1, M A Roggero, O Duombo, J M Gonzalez, R Tolle, O Koita, M Arevalo-Herrera, S Herrera, G Corradin.   

Abstract

In the present work, we analyze the recognition of synthetic polypeptides encompassing the aminoterminal (amino acids 22-125) and the carboxy terminal (289-390) regions of the circumsporozoite (CS) protein of Plasmodium falciparum by sera from donors living in endemic area of South America and Africa. Two populations were studied: one on the Colombian Pacific coast, with low endemicity for malaria; and a western African village exposed to a very intense transmission of P. falciparum. Antibodies directed to the two polypeptides were found at high titers in both populations. Furthermore, this response was observed in individuals lacking antibodies to the highly repetitive central sequence of the CS protein (NANP). The epitopes responsible for this recognition were mapped to the region 81-125 and 316-346 of the N- and C-termini, respectively. When the two populations were compared, both showed high titers of antibodies to the two flanking peptides. However, while 95% of the sera from African adults showed antibodies against the repeat region of the CS protein, only 37% of the Colombian adults studied had these antibodies. Furthermore, African donors of various ages exhibited different patterns of recognition of the two polypeptides. In African children less than five years of age, antibodies were found in comparable levels to Colombian adults; however, in older African donors, the response to NANP became dominant. These findings may reflect the skewing effect of the humoral response towards the central repetitive epitope under conditions of frequent exposure to malaria infections. The production of such polypeptides encompassing regions that contain multiple epitopes for antibodies, T helper, and cytotoxic T lymphocyte epitopes would be advantageous in the generation of new and more efficient malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8916800     DOI: 10.4269/ajtmh.1996.55.424

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

2.  Molecular cloning and characterization of an antigenic protein with a repeating region from Clonorchis sinensis.

Authors:  T Y Kim; S Y Kang; I Y Ahn; S Y Cho; S J Hong
Journal:  Korean J Parasitol       Date:  2001-03       Impact factor: 1.341

3.  High-density Peptide Arrays Help to Identify Linear Immunogenic B-cell Epitopes in Individuals Naturally Exposed to Malaria Infection.

Authors:  Thomas Jaenisch; Kirsten Heiss; Nico Fischer; Carolin Geiger; F Ralf Bischoff; Gerhard Moldenhauer; Leszek Rychlewski; Ali Sié; Boubacar Coulibaly; Peter H Seeberger; Lucjan S Wyrwicz; Frank Breitling; Felix F Loeffler
Journal:  Mol Cell Proteomics       Date:  2019-01-10       Impact factor: 5.911

4.  Unexpected fold in the circumsporozoite protein target of malaria vaccines.

Authors:  Michael B Doud; Adem C Koksal; Li-Zhi Mi; Gaojie Song; Chafen Lu; Timothy A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-30       Impact factor: 11.205

5.  Minimal role for the circumsporozoite protein in the induction of sterile immunity by vaccination with live rodent malaria sporozoites.

Authors:  Marjorie Mauduit; Rita Tewari; Nadya Depinay; Michèle Kayibanda; Eliette Lallemand; Jean-Marc Chavatte; Georges Snounou; Laurent Rénia; Anne Charlotte Grüner
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

6.  Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3.

Authors:  Aissatou Toure-Balde; Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Mouhamadou Ndiaye; Georgette Aribot; Adama Tall; Cheikh Sokhna; Christophe Rogier; Giampietro Corradin; Christian Roussilhon; Pierre Druilhe
Journal:  Infect Immun       Date:  2009-01-12       Impact factor: 3.441

7.  High Sporozoite Antibody Titers in Conjunction with Microscopically Detectable Blood Infection Display Signatures of Protection from Clinical Malaria.

Authors:  Vittoria Offeddu; Ally Olotu; Faith Osier; Kevin Marsh; Kai Matuschewski; Vandana Thathy
Journal:  Front Immunol       Date:  2017-05-08       Impact factor: 7.561

8.  The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled phase I trial.

Authors:  Régine Audran; Floriana Lurati-Ruiz; Blaise Genton; Hildur E Blythman; Opokua Ofori-Anyinam; Christophe Reymond; Giampietro Corradin; François Spertini
Journal:  PLoS One       Date:  2009-10-02       Impact factor: 3.240

9.  Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso.

Authors:  I Nebie; A Diarra; A Ouedraogo; A B Tiono; A T Konate; A Gansane; I Soulama; S Cousens; O Leroy; S B Sirima
Journal:  Parasite Immunol       Date:  2009-08       Impact factor: 2.280

10.  Rare PfCSP C-terminal antibodies induced by live sporozoite vaccination are ineffective against malaria infection.

Authors:  Stephen W Scally; Rajagopal Murugan; Alexandre Bosch; Gianna Triller; Giulia Costa; Benjamin Mordmüller; Peter G Kremsner; B Kim Lee Sim; Stephen L Hoffman; Elena A Levashina; Hedda Wardemann; Jean-Philippe Julien
Journal:  J Exp Med       Date:  2017-11-22       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.